<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472040</url>
  </required_header>
  <id_info>
    <org_study_id>BCX7353-204</org_study_id>
    <nct_id>NCT03472040</nct_id>
  </id_info>
  <brief_title>A Long Term Safety Study of BCX7353 in Hereditary Angioedema</brief_title>
  <acronym>APeX-S</acronym>
  <official_title>An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to evaluate the long term safety and effectiveness of oral
      treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and
      Type II HAE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The long term safety of oral BCX7353 capsules</measure>
    <time_frame>48 weeks</time_frame>
    <description>The number and percentage of subjects with treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of acute attacks of angioedema during treatment</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The durability of response to treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate if the rate of attacks remains consistent (durable) over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality of life (QoL) during treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>To measure changes in quality of life over time from baseline, assessed by use of an HAE-specific Angioedema QoL (AE-QoL) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction with medication during long term administration of BCX7353</measure>
    <time_frame>48 weeks</time_frame>
    <description>To measure satisfaction with study medication using the Treatment Satisfaction Questionnaire for Medication (TSQM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>HAE</condition>
  <condition>Prophylaxis</condition>
  <arm_group>
    <arm_group_label>BCX7353 110 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX7353 150 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX7353</intervention_name>
    <description>BCX7353 mg oral capsules administered once daily</description>
    <arm_group_label>BCX7353 110 mg once daily</arm_group_label>
    <arm_group_label>BCX7353 150 mg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects with HAE Type I or II who either have participated in a previous BCX7353
             study or, in selected countries, in the opinion of the Investigator are expected to
             derive benefit from an oral treatment for the prevention of angioedema attacks.

          -  Access to appropriate medication for treatment of acute attacks

          -  Acceptable effective contraception

          -  Written informed consent

        Key Exclusion Criteria:

          -  Pregnancy or breast-feeding

          -  Any clinically significant medical condition or medical history that, in the opinion
             of the Investigator or Sponsor, would interfere with the subject's safety or ability
             to participate in the study

          -  Any laboratory parameter abnormality that, in the opinion of the Investigator, is
             clinically significant and relevant for this study

          -  Discontinuation of study drug due to a hypersensitivity reaction BCX7353 in a prior
             study

          -  Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/
             anaphylaxis with unclear etiology

          -  Unacceptable noncompliance in a previous BCX7353 study (if applicable) as assessed by
             the Sponsor or Investigator

          -  Investigational drug exposure, other than BCX7353, within 30 days prior to the
             screening visit (or baseline if no screening visit)
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henriette Farkas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis University, Budapest, Hungary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study director</last_name>
    <phone>+1 919 859 1302</phone>
    <email>clinicaltrials@biocryst.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCX7353</keyword>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>HAE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

